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Abstract
Rationale The prefrontal cortex (PFC) and basal ganglia (BG) have been associated with cognitive stability and cognitive
flexibility, respectively. We hypothesized that increasing PFC dopamine tone by administering tolcapone (a catechol-O-
methyltransferase (COMT) inhibitor) to human subjects should promote stability; conversely, increasing BG dopamine tone
by administering bromocriptine (a D2 receptor agonist) should promote flexibility.
Objective We assessed these hypotheses by administering tolcapone, bromocriptine, and a placebo to healthy subjects who
performed a saccadic eye movement task requiring stability and flexibility.
Methods We used a randomized, double-blind, within-subject design that was counterbalanced across drug administration
sessions. In each session, subjects were cued to prepare for a pro-saccade (look towards a visual stimulus) or anti-saccade (look
away) on every trial. On 60% of the trials, subjects were instructed to switch the response already in preparation.We hypothesized
that flexibility would be required on switch trials, whereas stability would be required on non-switch trials. The primary measure
of performance was efficiency (the percentage correct divided by reaction time for each trial type).
Results Subjects were significantly less efficient across all trial types under tolcapone, and there were no significant effects of
bromocriptine. After grouping subjects based onVal158Met COMT polymorphism, we found thatMet/Met and Val/Met subjects
(greater PFC dopamine) were less efficient compared to Val/Val subjects.
Conclusions Optimal behavior was based on obeying the environmental stimuli, and we found reduced efficiency with greater
PFC dopamine tone. We suggest that greater PFC dopamine interfered with the ability to flexibly follow the environment.
Keywords Saccade . Dopamine . Prefrontal cortex . Basal ganglia . Tolcapone . Bromocriptine
Introduction
Among the myriad of processes that constitute Bcognitive
control^ (Miller and Cohen 2001; Fuster 2001; Cools and
D’Esposito 2011; Stuss 2011), two opposing processes
governing behavior have been described: cognitive stability
and cognitive flexibility. Cognitive stability refers to the ability
to establish and maintain a Btask set,^ so that goal-directed
behaviors can be executed despite interference from conflict-
ing alternative behaviors (Sakai 2008). This ability is thought
to be critically dependent upon the function of the prefrontal
cortex (PFC), which is known to be important to working
memory, rule representation, and resistance to distraction
(Miller and Cohen 2001; Fuster 2001; Cools and D’Esposito
2011). In contrast, cognitive flexibility refers to the ability to
override a task set in order to perform an alternative behavior
(Robbins 2007), and this ability is thought to be mediated by
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circuits involving the basal ganglia (BG) and the PFC (Cools
and D’Esposito 2011). While the BG do not operate in isola-
tion (as cortical sensory, motor, and association areas project
to the striatum (Gerfen and Surmeier 2011; Shipp 2017)), BG
circuits may have a particular role in assisting in the flexible
switching between responses (Robbins 2007).
Both stability and flexibility can be influenced significantly
by neuromodulators acting in the PFC and BG: dopamine, for
example, is a well-known modulator of cortico-basal ganglia
networks (Cools and D’Esposito 2009; Gerfen and Surmeier
2011), and it may differentially impact stability and flexibility
through its effects on different dopamine receptor subtypes
(Seamans and Yang 2004). In the PFC, dopamine D1 receptor
stimulation is thought to support the maintenance of informa-
tion, by promoting recurrent activity in PFC networks (there-
by facilitating stability), whereas D2 receptor stimulation is
thought to support flexibly switching between different repre-
sentations of information, by increasing the responsiveness to
new inputs (Durstewitz and Seamans 2008). D1 receptors are
thought to be more dominant than D2 receptors in the PFC,
however (Cools 2006; Cools and D’Esposito 2011), suggest-
ing that if dopamine tone is increased in PFC, there would be a
net increase in stability.
In comparison, the basal ganglia contains both D1 and D2
receptors on striatal medium spiny neurons, with D1 receptors
found predominantly on those neurons constituting the
Bdirect^ pathway, and D2 receptors are found predominantly
on these neurons constituting the Bindirect^ pathway
(Surmeier et al. 2007; Gerfen and Surmeier 2011). Models
of these direct (facilitatory) and indirect/hyperdirect
(inhibitory) pathways in the BG provide a sensible mechanism
to explain how the brain can override one response with an
alternative (Mink 1996; Nambu 2008). A well-known model
of BG function proposes that the direct pathway facilitates
cortical signals important for producing the desired behavior,
while the indirect pathway aids in inhibiting competing corti-
cal signals, and that the net action of dopamine is to boost the
facilitatory effect of the direct pathway (D1) and reduce the
inhibitory effect of the indirect pathway (D2) (Mink 1996;
Surmeier et al. 2007; Nambu 2008; Gerfen and Surmeier
2011). This model posits that dopamine excites striatal neu-
rons in the direct pathway through D1 receptors, while it in-
hibits striatal neurons in the indirect pathway through D2 re-
ceptors (Nambu 2008). The net result from this dual action of
dopamine would be the facilitation of a desired behavior, but
with the consequence that there would be reduced suppression
of other behaviors, promoting flexible switching to an alter-
native action.
Here, we test hypotheses about the relative roles of dopa-
mine in the PFC and basal ganglia with respect to cognitive
stability and flexibility during performance of a saccadic eye
movement task, where dopamine tone was manipulated phar-
macologically. We hypothesized that augmenting dopamine
tone in PFC in human subjects would favor D1 stimulation,
and hence, promote cognitive stability (Cools and D’Esposito
2011; Frank and Fossella 2011). In contrast, we hypothesized
that D2 stimulation (Cools 2006; Kvernmo et al. 2006; Cools
et al. 2007) would promote cognitive flexibility, primarily by a
basal ganglia mechanism.
To test our first hypothesis, we administered tolcapone, a
catechol-O-methyltransferase (COMT) inhibitor that prefer-
entially increases dopamine tone in the PFC because COMT
has a greater role in dopamine metabolism in the PFC com-
pared to the basal ganglia (Männistö and Kaakkola 1999;
Tunbridge et al. 2004). (We note that tolcapone could have
effects beyond PFC—for example, in the hippocampus
(Laatikainen et al. 2013)—but the important comparison here
is its relative action in the PFC compared to the BG).
Additionally, to evaluate a secondary and independent corre-
late of COMTactivity, we divided subjects based on the func-
tional Val158Met COMT polymorphism to assess differences
in behavior depending on relative COMT activity between
these groups of individuals. The Val allele results in greater
COMT activity, and hence greater degradation of dopamine
compared to the Met allele (Lachman et al. 1996; Chen et al.
2004).
To test our second hypothesis, we administered the dopa-
mine D2 agonist bromocriptine (Kimberg et al. 1997; Cools
2006; Kvernmo et al. 2006; Cools et al. 2007).While systemic
bromocriptine would have effects on flexibility in both the
PFC and BG, D2 receptors are found in relatively higher con-
centration in the BG (Cools 2006); thus, we hypothesized that
bromocriptine would have a greater effect on flexibility via
action on the indirect pathway of the BG.
Under the influence of tolcapone, bromocriptine, or place-
bo, subjects performed an interleaved pro-/anti-saccade task
that was designed to require both cognitive stability and cog-
nitive flexibility and was hypothesized to recruit PFC and BG
circuits accordingly. To perform a pro-saccade, subjects sim-
ply look towards a peripheral stimulus, but to perform an anti-
saccade, subjects must execute a voluntary eye movement in
the direction opposite to the peripheral stimulus (Hallett 1978;
Munoz and Everling 2004). Previous lesion, human neuroim-
aging, and physiology studies have shown that maintenance
of an anti-saccade task set depends critically upon the dorso-
lateral PFC (Pierrot-Deseilligny et al. 2005; Everling and
Johnston 2013). Saccade programming also involves the di-
rect and indirect pathways of the BG (Hikosaka et al. 2000;
Watanabe and Munoz 2011), and people with Parkinson’s
disease (PD), a primarily BG disorder, show anti-saccade def-
icits (Chan et al. 2005; Hood et al. 2007). An interleaved
pro-/anti-saccade also demands flexibility, due to the fact that
subjects must establish the appropriate task set (pro- or anti-)
on a trial-by-trial basis, based on an external cue (Munoz and
Everling 2004). Finally, efficient performance of pro- and
anti-saccades has been demonstrated to be sensitive to
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dopamine (Hood et al. 2007; Watanabe and Munoz 2011;
Cameron et al. 2012).
Here, we utilized a particular variant of the pro-/anti-sac-
cade task to further evoke flexibility in terms of overriding a
prepared behavior with an alternative (Cameron et al. 2007):
subjects are sometimes required to switch suddenly from a pro
(look towards)-saccade to an anti-saccade or from an anti-
saccade to a pro-saccade. Thus, on switch trials, one task set
must be inhibited, while another is initiated. We hypothesized
that switching behavioral responses in this fashion more ex-
plicitly recruits the BG, and have confirmed previously using
functional MRI, and by studying patients with Parkinson’s
disease, that the BG are important to this form of flexibility
(Cameron et al. 2009, 2010).
Taken together, we predicted that tolcapone would promote
stability, so would improve performance on non-switch trials,
particularly anti-saccades. Additionally, we hypothesized
tolcapone would have greater effects at improving performance
on such trials in subjects with the Val allele. In contrast, bromo-
criptine would promote flexibility, by acting on D2 receptors of
the BG, so as to facilitate performance on switch trials.
Methods
Subjects
All subjects gave written informed consent in accordance with
the Committee for the Protection of Human Subjects at the
University of California, San Francisco and University of
California, Berkeley. Subjects first underwent a history and
physical exam, as well as blood testing for liver function and
urine screening for drugs of abuse, to ensure that there were no
medical contraindications to tolcapone or bromocriptine use.
We ultimately invited 22 subjects to participate in the saccade
task, and 19 agreed to participate and were able to complete all
3 days. However, due to problems with poor eye-tracking
quality in some of the subjects on some days, a final total of
16 subjects provided data from all three sessions. These 16
subjects were in the age range of 21–36 (mean = 24), were all
right handed, and 11 were male.
Medications
Subjects were randomized in a double-blind, counterbalanced,
placebo-controlled fashion to receive placebo, a single
1.25 mg dose of bromocriptine, or a single 200 mg dose of
tolcapone on their first visit. The remaining treatments were
administered on their second and third visits, respectively,
such that every subject received each treatment on one of the
three study days. Because tolcapone can discolor the urine,
and therefore can potentially un-blind subjects, each capsule
was compounded with 25 mg of the B-vitamin riboflavin in
order to mask this effect. On each day, subjects were given the
drug in the morning. Subjects were thenmonitored throughout
the day, during which time they also performed a series of
cognitive tasks (unrelated to the present study, including a
food choice task and a delay discounting task) but always
ending with the saccade task presented here. Each subject
began the saccade task at approximately 5 h post drug admin-
istration and completed it by 6 h. Both dopaminergic drugs are
expected to have pharmacodynamically relevant serum con-
centrations for greater than 6 h (Dingemanse et al. 1994;
Nyholm 2006; Kvernmo et al. 2006).
Saccade task
We utilized a particular variant of a pro-/anti-saccade task
requiring subjects to switch suddenly from a pro-saccade to
an anti-saccade, or from an anti-saccade to a pro-saccade, on a
subset of trials (Cameron et al. 2007). We hypothesized that
switching a saccade response in this fashion more explicitly
recruits the facilitatory (direct) and inhibitory (indirect) path-
ways of the BG and have confirmed using functional MRI in
healthy subjects and patients with Parkinson’s disease that the
basal ganglia are critical for this form of flexibility (Cameron
et al. 2009, 2010).
Subjects performed 12 blocks of 20 trials of a pro-/anti-
saccade task on each day. A neutral cross cue (2 s) was pre-
sented. Subsequently, a green or red cross (2 s) was presented
instructing subjects to adopt a pro-saccade (look towards) or
anti-saccade (look away) task set (Fig. 1). Then, a peripheral
stimulus (a blue circle of 1 degree of visual angle) appeared at
12° pseudorandomly to the left or right for 1.5 s. On 60%of the
trials, the instruction switched to the opposite color at 100, 150,
or 200 ms after peripheral stimulus onset. These switch times
were chosen because previous evidence suggested they are in
the critical time for producing switch costs, indicating that an
initial response program had to be switched (Cameron et al.
2007, 2009). The 60% switch frequency was chosen because
we did not want non-switch trials to be asymmetrically easier
to perform than switch trials, and we also wanted to increase
the switch trial frequency to have sufficient power to examine
differences across the switch times. Importantly, our previous
study showed that switch costs are produced with switch trials
up to 75% in probability, demonstrating that predictability can-
not override the tendency to prepare the instructed response,
resulting in a cost for switching (Cameron et al. 2007).
Subjects were told to be quick, but accurate, and to obey the
final instruction color. Another neutral cross (1.5 s) marked the
return to fixation and ended each trial.
Eye tracking and stimuli
An Eyelink 1000 (SR Research) system was used to track the
right eye at a sample rate of 500 Hz. A CRT monitor with a
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1024 × 768 resolution was used to present the visual targets,
and the task was programmed in MATLAB 2011b using
Psychtoolbox.
Analysis
Our primary analysis of interest was Befficiency,^ which is a
combined measure of accuracy (i.e., correct direction (%))
divided by reaction time (ms) (Machizawa and Driver 2011).
However, we also analyzed reaction times and accuracies
separately.
A linear mixed effects model was performed in R 3.1.2,
treating efficiency (or reaction time or accuracy) as the depen-
dent variable, with initial task (pro or anti) and switch condi-
tion (non-switch or switch) as fixed effects. For this analysis,
we collapsed across the three different possible onset times for
the switch command. We accounted for possibly different ef-
fects for the drugs on a given subject, by treating the subject as
a random effect and drug (bromocriptine, placebo, tolcapone)
as a random slope. Post hoc multiple comparisons of means
were employed using the Tukey’s method, after performing an
analysis of deviance F-test on the results of the mixed-effects
model in R.
We performed three secondary analyses on the saccade
behaviors as follows. First, we examined the effects of the
COMT genotype (Val/Val N = 4; Val/Met, N = 7; Met/Met
N = 5) (collapsed across Switch Time) on efficiency. Second,
we examined the effects of Switch Time (100, 150, 200 ms)
on efficiency as a fixed effect in the above regression analysis
but using only the switch trials. Finally, to explore whether the
drugs influenced vigilance (the ability to maintain attention),
we divided the runs into the first and second halves, adding the
factor half to the initial task × switch time × drug models for
efficiency, reaction times, and accuracy separately. (Changes
in vigilance can be assessed by performance decrements in
reaction time and/or accuracy as the time-on-task increases
(Lim et al. 2012)).
In addition to this method to explore vigilance effects, we
also examined performance (number of correct answers com-
pleted in 90 s) on the pen and paper version of the Digit
Symbol Substitution Test (DSST), a component of the
Wechsler Adult Intelligence Scale. The DSST measures
sustained attention, response speed, visuomotor coordination,
and set shifting (Lezak et al. 2004), so we used this test as a
general measure of motor and cognitive functions to comple-
ment the saccade task. The DSST was performed prior to the
saccade task (approximately 4–5 h after drug administration).
Results
For performance efficiency, there was a main effect of drug
(F(2, 35.6) = 4.00, P < 0.05), initial task (Pro or Anti; F(1,
149.3) = 8.29, P < 0.01), and switch condition (Switch or
Non-switch; F(1, 149.3) = 82.62, P < 0.001). There was also
an initial task × switch condition interaction (F(1, 149.3) =
Neutral 
Cue 
(2 s) 
Neutral
Cue
(1.5 s)
Instruction
Cue 
(2 s)
Response
Period
(1.5 s)
peripheral stimulus
pro 
switch time
(at 100, 150, 200 ms 
from peripheral stimulus onset )
time
anti
anti(left)
anti(left)-to-pro(right)
pro(right)
pro(right)-to-anti(left)
anti
anti
anti
pro
pro
pro
Trial
Type
anti
pro
Fig. 1 Paradigm and timing of
trial events. Shown are examples
of four trial types in which the
peripheral stimulus was on the
right side. On switch trials, the
switch to the opposite task could
occur at 100, 150, or 200 ms
following peripheral stimulus
onset, and subjects were
instructed to respond to the final
instruction only
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22.67, P < 0.001), but no other interactions were significant
(all P’s > 0.21).
These results demonstrate that drug influenced performance
efficiency across all trial types (Fig. 2), such that tolcapone
reduced efficiency as compared to placebo (z = − 2.85,
P < 0.05), but efficiency did not differ between bromocriptine
and placebo (z = − 1.42, P = 0.32). The main effects and inter-
actions involving initial task and switch condition are consistent
with previous observations with this task (Cameron et al. 2007,
2009), such that performing an anti-saccade is less efficient
(greater latency, increased direction errors) than performing a
pro-saccade, switch trials are less efficient than non-switch trials
(especially during switches from a pro to an anti-saccade), and
efficiency is highest for non-switch pro-saccades.
Next, we assessed drug effects on reaction times and accu-
racy (i.e., percentage correct direction) separately. For saccade
reaction time (Fig. 3a), there was a significant main effect of
drug, F(2, 10.7) = 35.65, P < 0.001, as subjects were slower
under tolcapone compared to placebo, z = 2.58, P < 0.05, but
not slower under bromocriptine compared to placebo (z = 1.57,
P = 0.20). There were also significant main effects of initial
task, F(1, 149.0) = 6.38, P < 0.05, and switch condition, F(1,
149.0) = 21.24, P < 0.001, and a significant initial task by
switch condition interaction, F(1, 149.0) = 7.25, P < 0.001. In
summary, the results with reaction time mirror the results with
efficiency, such that anti-saccades are performed more slowly
than pro-saccades, switch trials are slower than non-switch tri-
als, and reaction times are fastest for non-switch pro-saccades.
In comparison, there were no significant effects of drug on
accuracy, P > 0.13 (Fig. 3b), but there was a main effect of
switch condition, F(1, 150.0) = 67.53, P < 0.001, and a signif-
icant initial task by switch condition interaction, F(1, 150.0) =
20.44, P < 0.001. This finding shows that accuracy on the
tasks was affected in a predictable fashion (i.e., worse accura-
cy on anti-saccades and switch trials, such that pro-to-anti-
saccade switch trials were performed with the worst accuracy
(Fig. 3b)).
To further explore our finding of a main effect of drug on
performance efficiency, we divided subjects based on COMT
genotype (Val/Val, Val/Met, Met/Met). We found a main ef-
fect of COMT genotype (F(2, 13.0) = 5.16, P < 0.05; Fig. 4);
Val/Val subjects were more efficient than Val/Met subjects
(z = 2.93, P < 0.01) and Met/Met subjects (z = 2.80,
P < 0.05). There was also a significant COMT by switch con-
dition interaction (F(2, 129.2) = 7.02, P < 0.001, as Val/Val
subjects showed smaller performance differences between
switch and non-switch trials. However, there was no COMT
by drug interaction (P = 0.24).
Additional secondary analyses were performed to ensure
that the task was being performed as expected. We found a
main effect of switch time, F(2, 224.1) = 17.7, P < 0.001, be-
cause efficiency decreased as switch time increased; however,
there were no interactions of switch time with the other
variables (drug or initial task) P > 0.19. Next, by dividing
the data into the first and second halves, we also assessed
whether vigilance effects were present. We found results that
mirrored those reported above in the primary analyses but no
significant main effects or interactions regarding half, though
amain effect of half for reaction time approached significance,
F(1,308.0) = 3.20, P = 0.07. (This trend resulted because reac-
tion times in the second half were slower by 17 ms, collapsed
across all trial types). Additionally, to rule out the possibility
that tolcapone had general effects on vigilance, subjects per-
formed the DSST test. We did observe that the number of
correct symbols completed on the DSST under bromocriptine
(mean 57.1 ± standard error 3.4) was significantly fewer,
t(14) = 3.06, P < 0.01, than the number completed under place-
bo (64.3 ± 3.8), but there was no difference between tolcapone
(64.5 ± 3.6) and placebo, t(15) = 0.16, P = 0.44. We found also
that the mean efficiency scores (collapsed across trial type) for
the saccade task under each drug correlated positively with the
DSST (Table 1), indicating DSSTwas an appropriate psycho-
metric test for comparison to the saccade task.
Discussion
In this study, human subjects performed a saccade task that
required them to switch a prepared pro- or anti- saccade to the
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alternative on a subset of trials. We observed following the
administration of tolcapone (which increases PFC dopamine
tone) that subjects exhibited reduced overall performance ef-
ficiency and longer reaction times. Consistent with this find-
ing, we also observed that subjects with the Val/Val genotype
of the COMT gene (reduced PFC dopamine tone) were more
efficient overall than subjects with the Val/Met or Met/Met
genotypes. However, we did not observe behavioral effects
following administration of bromocriptine (a D2 agonist),
nor did we observe significant effects depending on response
type (i.e., pro- or anti-saccade, or non-switch or switch) on
either drug. The results suggest that there was a general
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detrimental influence of greater PFC dopamine on the ability
to perform the task efficiently, as the result of tolcapone ad-
ministration or of COMT genotype.
Previous studies have provided a framework for how
tolcapone may improve performance by augmenting PFC do-
pamine tone in tasks, such as working memory tasks, which
are known to be dependent on PFC function. The fact that
tolcapone improved response times in working memory tasks
(where information must be stored online across trials) (Apud
et al. 2007; Giakoumaki et al. 2008) shows howmodulation of
PFC dopamine tone can have general effects on cognitive
performance, rather than those limited to a response in a par-
ticular trial. Other studies on the effects of tolcapone have
utilized the COMT polymorphism to show that there is an
interaction between tolcapone and presumptive baseline do-
pamine tone, such that tolcapone improves performance in N-
back working memory tasks in Val/Val individuals (who have
relatively reduced PFC dopamine tone) (Apud et al. 2007;
Giakoumaki et al. 2008; Cools and D’Esposito 2011).
In the present study, we observed evidence for generally
worse performance under tolcapone, and we did not observe a
significant COMT genotype by drug interaction (which could
be the result of a lack of power). Because tolcapone increased,
rather than decreased reaction times, these general effects
were not likely related to dopamine acting on the motor sys-
tem, which should facilitate responding as found in studies of
Parkinson’s patients on dopaminergic medications (Mink
1996; Cools 2006; Cameron et al. 2012), and in one study
where levodopa was provided to healthy adults (Rihet et al.
2002). (We note, however, that unlike levodopa, tolcapone is
expected to have more local influences on behavior (i.e., PFC)
whereas levodopa might have more widespread influences in
the brain as a precursor to dopamine and norepinephrine pro-
duction (Cools 2006)). Rather, our results suggest that
tolcapone was detrimental to cognitive aspects of performance
(Cools and D’Esposito 2011). Consistent with this idea, in
another study using the same tolcapone dose, we also found
no evidence for motor changes (Kayser et al. 2012) despite
influences on reward-related decision processes.
One possible effect of tolcapone, however, is that it in-
creased fatigue, or decreased vigilance, resulting in detriments
to efficiency or reaction time. In a rat model of attention deficit
hyperactivity disorder-combined type (ADHD-C), tolcapone
increased sustained attention and vigilance in ADHD-C rats,
but it decreased vigilance in healthy rats (Tomlinson et al.
2015). Lim et al. (2012) found a time-on-task effect where
Met/Met subjects (greater PFC dopamine) showed greater de-
cline in performance vigilance, but COMT polymorphism did
not affect ratings of mood or fatigue (Lim et al. 2012). These
results suggest that greater PFC dopamine can result in worse
task performance over time, possibly related to decreased vig-
ilance. However, in our analyses in which we divided trials
into the first and second half of the task, we did not find
significant evidence that tolcapone affected vigilance, nor
Table 1 Mean saccade task
efficiency and DSST scores Bromocriptine Placebo Tolcapone
Subject Efficiency DSST Efficiency DSST Efficiency DSST
1 0.171 56 0.140 66 0.148 65
2 0.203 59 0.225 58 0.214 73
3 0.175 58 0.158 65 0.159 57
4 0.167 72 0.169 76 0.162 82
5 0.172 56 0.197 63 0.090 65
6 0.182 – 0.170 57 0.171 56
7 0.145 46 0.163 45 0.149 51
8 0.092 48 0.173 43 0.081 38
9 0.076 35 0.143 46 0.154 44
10 0.155 67 0.143 74 0.136 72
11 0.168 65 0.155 69 0.124 68
12 0.157 60 0.164 66 0.146 64
13 0.157 61 0.144 77 0.136 75
14 0.173 41 0.185 76 0.153 81
15 0.226 47 0.132 46 0.145 51
16 0.198 85 0.353 101 0.191 90
Mean 0.163 57.1 0.176 64.3 0.147 64.5
r 0.45 0.58a 0.44
P value 0.096 0.018 0.091
a Significant
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did we find a difference between performance following
tolcapone and placebo on the DSST.
Given these considerations, we propose that augmentation
of PFC dopamine paradoxically improved cognitive control
that was disadvantageous to performance (Diamond 2013).
As in most laboratory paradigms, subjects were required to
focus on the task and avoid switching their attention to irrel-
evant distractions or internal motivational states that would
impair overall performance. This Bmeta-control^ modulates
the strength of top-down attention and cognitive flexibility,
which in turn affects how easily external information gains
access to working memory (Goschke and Bolte 2014). In the
present study, subjects needed to prepare an instructed re-
sponse to a peripheral target but at the same time monitor
the fixation point for a possible change to the instructed be-
havior. While this necessitates focused attention, studies in
performance Bchoking^ show that over-focusing attention on
the process of performing the task interferes with behaviors
that should be more automatically driven (Kimble and
Perlmuter 1970; Lewis and Linder 1997). The elevated re-
sponse times supports the point that automaticity was reduced.
This proposal is supported bymodels on reactive compared
to proactive inhibitory control (Aron 2011; Braver 2012;
Schall and Godlove 2012). Reactive inhibitory control occurs
in response to an exogenous stimulus (e.g., the cue to switch
task) (Braver 2012). There are many possible sources of reac-
tive inhibitory control that could be engaged by the cue: the
Bhyperdirect^ pathway of the BG (Aron and Poldrack 2006;
Aron 2011), Bfixation^ neurons in the frontal eye fields and
superior colliculus (Munoz and Everling 2004; Schall and
Godlove 2012), and substantia nigra pars reticulata (SNr) out-
put neurons of the BG (Hikosaka et al. 2000).
In contrast, proactive inhibitory control refers to Bsustained
and anticipatory maintenance^ of goal-relevant information,
before cognitively demanding events occur (Braver 2012). In
the present study, subjects had information that switches were
relatively frequent (60%) and could therefore anticipate the
possibility of having to switch their response. Empirical evi-
dence suggests that this type of prediction engages proactive
inhibitory control (Aron 2011), because latencies on Bgo^
trials (where a response is required) increase when the fre-
quency of Bstop^ trials increases. Likewise, we have found
that when subjects move from blocked designs (pro- or anti-
saccade trials separately), to ones in which trials are inter-
leaved, to ones that include switch trials, latency increases
parametrically (Cameron et al. 2010). We have also found that
decreasing switch trial probability (from 75 to 50 to 25%)
results in increased reaction time switch costs (Cameron
et al. 2007), implying that subjects use proactive inhibitory
control to modulate their behavior. Reaction times in the cur-
rent study exceeded 400 ms (Fig. 3a), which is abnormally
slow compared to simpler saccade tasks (Munoz and Everling
2004), but consistent with the previous studies employing this
paradigm (Cameron et al. 2007, 2010). Overall, our findings
support a mechanismwhereby greater PFC dopaminergic tone
reflects greater proactive inhibitory control.
The PFC is proposed to be the source of proactive inhibi-
tory control signals (Braver 2012) (albeit potentially via
fronto-striatal circuits (Aron 2011)), and evidence suggests
that PFC-BG circuits are important when general rather than
action-specific inhibition is required (Smittenaar et al. 2013).
In the oculomotor system, lateral PFC is thought to be critical
for suppressing a pro-saccade response (Pierrot-Deseilligny
et al. 2005), by establishing anti-saccade task set signals to
bias the subject against eliciting a more automatic pro-saccade
before the stimulus appears (Everling and Johnston 2013).
Increased lateral PFC activity has been observed prior to
probe (test) stimuli in a working memory task, primarily when
the expectancy of an Binterference^ trial was high (i.e., having
to respond that a probe was not part of the memory set)
(Burgess and Braver 2010; Braver 2012); this finding suggests
that proactive inhibitory control relates to anticipatory activity
in PFC, particularly in advance of more cognitively demand-
ing tasks. Studies employing Stroop paradigms have also im-
plicated circuits involving the lateral PFC as having a role in
sustained proactive control processes when the predictability
of incongruent trials is high (De Pisapia and Braver 2006;
Krug and Carter 2012). Importantly, proactive inhibitory con-
trol is proposed to be dopamine dependent (Braver 2012).
Accordingly, subjects with the Val allele are less efficient than
those with the Met allele in tasks requiring proactive, rather
than reactive inhibitory control, as subjects with the Val allele
exhibit greater recruitment of lateral PFC than Met carriers
(Jaspar et al. 2014).
In summary, evidence supports our proposal that increasing
PFC dopamine facilitates proactive inhibitory control, which
may result in an over-focusing of attention and thus sub-
optimal performance in the saccade task. The consequence
would be an Boverdose^ on stability, decreasing the ability
to adapt to environments where reacting to frequent changes
with behavioral modifications would be more efficient
(Braver 2012).
Models of dopamine’s action on receptor subtypes support
such a hypothesis. First, evidence suggests PFC neurons are
more responsive to tonic dopamine signals (rather than fast-
acting phasic signals); thus, increased PFC dopamine follow-
ing tolcapone administration could have augmented more
general attentional states (Puig et al. 2014). Second, according
to the Bdual-state^ theory, optimal dopamine levels favor D1
receptor-mediated stabilization, but sub- or supra-optimal
levels favor D2 receptor-mediated flexibility (Durstewitz and
Seamans 2008; Cools 2015). This is because PFC networks
are differentially affected by D1 or D2 receptor stimulation,
depending on recurrent activity, such that supra-optimal D1
stimulation is detrimental because it renders the system less
sensitive, and in extreme cases immune, to new information
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(Durstewitz and Seamans 2008). Finally, according to
Binverted-U^models, increasing dopamine can move the cog-
nitive control system from a state promoting destabilization
and flexibility, to a state beneficial to stabilization and focused
attention (though then further back towards a state of
destabilization; Noudoost and Moore 2011; Arnsten et al.
2012; Cools 2015).
Given these relationships between dopamine’s effects on
D1 and D2 receptors in PFC, we must also consider potential
D2 effects from tolcapone. However, D2 effects are unlikely
to fully explain our results for at least three reasons. First,
reduced performance efficiency due to potential action on
D2 receptors should have been evident with bromocriptine
(unless the dosage was ineffective, discussed below).
Second, we did not observe a benefit on switch trials under
tolcapone (i.e., switching proactively did not actually benefit
explicitly cued switch trials; Armbruster et al. 2012). Third,
reaction times, and not direction accuracy, mirrored those of
efficiency, showing that subjects had slower reaction times
under tolcapone, rather than an increased frequency of
switching errors, which might be expected from a D2-
receptor effect of increased flexibility.
Finally, we hypothesized that bromocriptine would im-
prove flexibility by acting primarily on D2 receptors in
the basal ganglia (BG) (Cools et al. 2007; Surmeier et al.
2007), but we did not observe significant effects at the
trial-type level or at the general level. Several studies
have shown that bromocriptine influences cognitive per-
formance, in particular in tasks requiring flexible updating
of information (Kimberg et al. 1997; Cools et al. 2007;
Cools and D’Esposito 2011) or in those that require resis-
tance to distracting information (Bloemendaal et al.
2015). These effects of bromocriptine imply a mechanism
of action on D2 receptors in the PFC (Cools et al. 2007;
Puig et al. 2014; Bloemendaal et al. 2015) and in the BG
(Cools et al. 2008). While it is possible that bromocriptine
acted on D2 receptors in the PFC, PFC D2 receptors are
less abundant than in the striatum (Cools 2006) and are
found on output cells that project to the striatum itself
(Cools and D’Esposito 2011). In any case, action of bro-
mocriptine on D2 receptors would be expected to promote
flexibility rather than stability.
It is possible that the effects of bromocriptine in the brain
were reduced given that we administered the task 5 h after
ingestion of the medication, based on pharmacokinetics where
bromocriptine’s elimination half-life is between 3 and 7 or 8 h
(Nyholm 2006; Kvernmo et al. 2006). However, we did ob-
serve a significant effect of bromocriptine in this time window
(around 5 h) on DSST performance. Likewise, it is possible
that the low dose (1.25 mg) that we administered was ineffec-
tive, although we have found significant behavioral effects at
this dosage in other studies (Cools et al. 2007; Bloemendaal
et al. 2015). Nevertheless, other studies have failed to find
significant effects at this dosage with tasks performed within
3 h after ingestion (Winkel et al. 2012; Stelzel et al. 2013).
Thus, if our null finding is real, we propose that while
bromocriptine likely influenced indirect pathway (D2) signals
in the BG, the relative lack of agonistic action on the D1-
receptor-dominated direct pathway likely suggests that flexi-
ble switching was not facilitated optimally. One extension to a
standard BGmodel (Mink 1996) proposes that the hyperdirect
pathway (a faster conduction route from cortex to the subtha-
lamic nucleus of the indirect pathway) is important for abrupt-
ly suppressing no-longer relevant behavior (Isoda and
Hikosaka 2008), but it is the direct pathway that is important
for activating the desired behavior (Nambu 2008). This expla-
nation is supported by recent findings by Bestmann and col-
leagues, who found that a high (2.5 mg) dose of the D1/D2
receptor antagonist haloperidol impaired switching to a novel
motor response after subjects over-learned stimulus-response
mappings in a probabilistic task (Bestmann et al. 2015).
Lower doses (hypothesized to only act on D2 receptors) and
the D2 receptor antagonist sulpiride did not have such effects,
leading to the conclusion that motor system flexibility requires
action on both the D1 and D2 receptors of the direct and
indirect pathways, respectively.
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